<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511427719</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511427719</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Short Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Multiple sclerosis and amyotrophic lateral sclerosis: is there a link?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Etemadifar</surname><given-names>Masoud</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511427719">1</xref>
<xref ref-type="aff" rid="aff2-1352458511427719">2</xref>
<xref ref-type="aff" rid="aff3-1352458511427719">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Abtahi</surname><given-names>Seyed-Hossein</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511427719">1</xref>
<xref ref-type="aff" rid="aff4-1352458511427719">4</xref>
<xref ref-type="aff" rid="aff7-1352458511427719">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Akbari</surname><given-names>Mojtaba</given-names></name>
<xref ref-type="aff" rid="aff5-1352458511427719">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Maghzi</surname><given-names>Amir-Hadi</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511427719">1</xref>
<xref ref-type="aff" rid="aff2-1352458511427719">2</xref>
<xref ref-type="aff" rid="aff4-1352458511427719">4</xref>
<xref ref-type="aff" rid="aff6-1352458511427719">6</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511427719"><label>1</label>Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan, Iran.</aff>
<aff id="aff2-1352458511427719"><label>2</label>Isfahan Neurosciences Research Centre, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.</aff>
<aff id="aff3-1352458511427719"><label>3</label>Department of Neurology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.</aff>
<aff id="aff4-1352458511427719"><label>4</label>Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.</aff>
<aff id="aff5-1352458511427719"><label>5</label>Department of Epidemiology and Statistics, Isfahan University of Medical Sciences, Isfahan, Iran.</aff>
<aff id="aff6-1352458511427719"><label>6</label>Neuroimmunology Unit, Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK.</aff>
<aff id="aff7-1352458511427719"><label>7</label>Isfahan Medical Students Research Center (IMSRC), Isfahan University of Medical Sciences, Isfahan, Iran.</aff>
<author-notes>
<corresp id="corresp1-1352458511427719">Amir-Hadi Maghzi, Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Multiple Sclerosis Clinic, Al-Zahra Hospital, Isfahan University of Medical Sciences, Soffeh Street, Isfahan, Iran 81744. Email: <email>Maghzi@edc.mui.ac.ir</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>6</issue>
<fpage>902</fpage>
<lpage>904</lpage>
<history>
<date date-type="received">
<day>18</day>
<month>1</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>7</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>5</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>To date, there are no reports studying the rate of amyotrophic lateral sclerosis (ALS) in relatives of multiple sclerosis (MS) patients and vice versa. This study was designed to look into this issue using two population-based databases of MS and ALS in Isfahan province of Iran. We have searched for any first, second or third degree familial kinship between the Isfahan MS Society database and Isfahan ALS population. We compared the rate of ALS among the population of first degree relatives of MS patients, with the crude prevalence of ALS in the general population of Isfahan. On the other hand, a reverse analysis was carried out to compare the prevalence of MS in Isfahan with its rate amongst the first degree relatives of ALS patients. We found 10 families among which five had first degree kinship. The rate of the diseases was significantly higher in both comparisons among the family members (<italic>p</italic> &lt; 0.00001) and an odds ratios of more than 67 in both calculations showed a several-fold increase of ALS occurrence in the first degree relatives of MS patients and vice versa. In our study relatives of MS patients were significantly more prone to ALS and vice versa. This could give clues about the common features that the two disease share. Both diseases have an environmental and genetic component and these results mostly point toward genetic similarities.</p>
</abstract>
<kwd-group>
<kwd>amyotrophic lateral sclerosis</kwd>
<kwd>Isfahan – Iran</kwd>
<kwd>multiple sclerosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458511427719" sec-type="intro">
<title>Introduction</title>
<p>Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system (CNS) which is caused by the interaction of genetic and environmental components.<sup><xref ref-type="bibr" rid="bibr1-1352458511427719">1</xref>,<xref ref-type="bibr" rid="bibr2-1352458511427719">2</xref></sup> Recently, a degenerative component has been proposed for MS which is thought to precede the autoimmune processes.<sup><xref ref-type="bibr" rid="bibr3-1352458511427719">3</xref></sup> About 10–25% of patients have another affected family member and relatives of MS patients are at an increased risk of acquiring the disease.<sup><xref ref-type="bibr" rid="bibr1-1352458511427719">1</xref></sup></p>
<p>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease involving both upper and lower motor neurons of the CNS with an unknown etiology. The disease usually starts during mid-life and results in progressive muscular paralysis with a short survival of 2–5 years. Nearly 5–10% of patients have another affected relative in their family.<sup><xref ref-type="bibr" rid="bibr4-1352458511427719">4</xref></sup></p>
<p>Familial clustering of different diseases could indicate shared risk factors. Previous explanatory studies have suggested a possible familial aggregation between MS and ALS;<sup><xref ref-type="bibr" rid="bibr5-1352458511427719">5</xref>,<xref ref-type="bibr" rid="bibr6-1352458511427719">6</xref></sup> however, there are no reports studying simultaneously the rate of ALS in relatives of MS patients and vice versa. As a result, this study was designed to look into this issue using two population-based databases of MS and ALS in Isfahan province of Iran.</p>
</sec>
<sec id="section2-1352458511427719" sec-type="methods">
<title>Methods</title>
<p>We have previously reported the incidence and prevalence of MS and ALS in Isfahan province in 2006 through collecting the data of nearly all living MS and ALS patients in the province.<sup><xref ref-type="bibr" rid="bibr7-1352458511427719">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458511427719">8</xref></sup> Details of case ascertainment and study designs were published previously.<sup><xref ref-type="bibr" rid="bibr7-1352458511427719">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458511427719">8</xref></sup> We have searched for any first, second or third degree familial kinship between the Isfahan MS Society database among the 1718 patients registered,<sup><xref ref-type="bibr" rid="bibr7-1352458511427719">7</xref></sup> and the Isfahan ALS population of 72 patients.<sup><xref ref-type="bibr" rid="bibr8-1352458511427719">8</xref></sup> All surveyed patients were alive on the prevalence dates of the studies and families in which the MS or ALS index case has passed away before the prevalence dates of the studies were not included in this study nor in the original epidemiological studies for the calculation of prevalence figures.<sup><xref ref-type="bibr" rid="bibr7-1352458511427719">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458511427719">8</xref></sup> Institutional ethical approval was granted and patients’ written informed consent was obtained for this study.</p>
<p>We then compared the rate of ALS among the population of first degree relatives of MS patients, with the crude prevalence of ALS in the general population of Isfahan. On the other hand, a reverse analysis was carried out to compare the crude prevalence of MS with its rate amongst the first degree relatives of ALS patients. The number of first degree relatives of MS and ALS patients was estimated using the average family size of the Isfahan population (3.72), according to 2006 national census data subtracting the index case (2.72). Unfortunately, data needed for estimation of total number of second and third degree relatives was unavailable through the census data. The significance of these comparisons was tested by employing the chi-square test. In both calculations, we also calculated the odds ratio (OR) of the disease in the first degree relatives to the prevalence in the general population. Data analyses were carried out by PASW-v.18.00 and MedCalc-v.10 software and a <italic>p</italic> value of &lt; 0.05 was regarded as statistically significant.</p>
</sec>
<sec id="section3-1352458511427719" sec-type="results">
<title>Results</title>
<p>A total of 10 families were found in our search of whom all MS and ALS patients were alive on the prevalence dates. Five (Nos. 1–5) first degree, three (Nos. 6–8) second degree and two (Nos. 9, 10) third degree kinships were found between MS and ALS populations. Demographic and clinical features of affected members of these families are summarized in <xref ref-type="table" rid="table1-1352458511427719">Table 1</xref>. All of our ALS and MS cases in the studied families were in sporadic forms. The ALS case in family No. 1 also had developed Addison’s disease before developing ALS. Moreover, in family No. 7, the daughter of the MS index case developed systemic lupus erythematous (SLE).</p>
<table-wrap id="table1-1352458511427719" position="float">
<label>Table 1.</label>
<caption><p>Demographic and clinical features of 10 families’ paired members (ALS and MS cases) with a first, second or third degree kinship.</p></caption>
<graphic alternate-form-of="table1-1352458511427719" xlink:href="10.1177_1352458511427719-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Family number</th>
<th align="left">1</th>
<th align="left">2</th>
<th align="left">3</th>
<th align="left">4</th>
<th align="left">5</th>
<th align="left">6</th>
<th align="left">7</th>
<th align="left">8</th>
<th align="left">9</th>
<th align="left">10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree of kinship (MS/ALS)</td>
<td>1 (Son/father)</td>
<td>1 (Son/father)</td>
<td>1 (Brother/sister)</td>
<td>1 (Sister/brother)</td>
<td>1 (Daughter/mother)</td>
<td>2 (Nephew/aunt)</td>
<td>2 (Nephew/uncle)</td>
<td>2 (Nephew/uncle)</td>
<td>3 1st cousin</td>
<td>3 1st cousin</td>
</tr>
<tr>
<td>Sex of MS index case</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>Sex of ALS index case</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Birth date of MS index case</td>
<td>1980</td>
<td>1963</td>
<td>1951</td>
<td>1949</td>
<td>1971</td>
<td>1974</td>
<td>1966</td>
<td>1967</td>
<td>1976</td>
<td>1973</td>
</tr>
<tr>
<td>Birth date of ALS index case</td>
<td>1949</td>
<td>1943</td>
<td>1953</td>
<td>1954</td>
<td>1951</td>
<td>1956</td>
<td>1948</td>
<td>1945</td>
<td>1961</td>
<td>1966</td>
</tr>
<tr>
<td>Age at MS onset</td>
<td>20</td>
<td>37</td>
<td>39</td>
<td>46</td>
<td>28</td>
<td>29</td>
<td>32</td>
<td>29</td>
<td>18</td>
<td>29</td>
</tr>
<tr>
<td>Age at ALS onset</td>
<td>56</td>
<td>60</td>
<td>52</td>
<td>51</td>
<td>55</td>
<td>50</td>
<td>56</td>
<td>60</td>
<td>43</td>
<td>38</td>
</tr>
<tr>
<td>MS onset presentation</td>
<td>Diplopia, ataxia</td>
<td>Paresthesia</td>
<td>Optic neuritis</td>
<td>Paresthesia</td>
<td>Facial palsy, diplopia</td>
<td>Hemiparesia</td>
<td>Paraparesia</td>
<td>Diplopia</td>
<td>Diplopia, optic neuritis</td>
<td>Paresthesia</td>
</tr>
<tr>
<td>MS pattern</td>
<td>SP</td>
<td>RR</td>
<td>SP</td>
<td>SP</td>
<td>RR</td>
<td>RR</td>
<td>RR</td>
<td>SP</td>
<td>RR</td>
<td>RR</td>
</tr>
<tr>
<td>ALS presentation</td>
<td>Limb onset</td>
<td>Limb Onset</td>
<td>Limb onset</td>
<td>Bulbar onset</td>
<td>Bulbar onset</td>
<td>Limb onset</td>
<td>Limb onset</td>
<td>Bulbar onset</td>
<td>Limb onset</td>
<td>Limb onset</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511427719">
<p>F: female, M” male, RR: relapsing–remitting, SP: Secondary progressive</p></fn>
</table-wrap-foot>
</table-wrap>
<p>According to the average family size of people living within Isfahan, the total number of first degree relatives of MS (1718) and ALS (72) patients was estimated at about 4673 and 196 individuals respectively. As a result, the rate of ALS in first degree relatives of MS patients would be 5/4673, which, compared with the crude prevalence of ALS in Isfahan province (1.57/100,000),<sup><xref ref-type="bibr" rid="bibr8-1352458511427719">8</xref></sup> was significantly greater (<italic>p</italic> &lt; 0.00001, χ<sup>2</sup> = 307.16). We also calculated an OR of 67.7 (95% CI: 27.3–167.8), showing that the first degree relatives of MS patients were more likely to develop ALS. On the other hand, the rate of MS among first degree relatives of ALS patients would be 5/196, which, compared with the crude prevalence of MS in Isfahan in 2006, was significantly higher (<italic>p</italic> &lt; 0.00001, χ<sup>2</sup> = 327.7) with an OR of 69.4 (95% CI: 28.54–168.97).</p>
</sec>
<sec id="section4-1352458511427719" sec-type="discussion">
<title>Discussion</title>
<p>In this study we found that first degree relatives of MS patients are significantly more prone to ALS and vice versa. The same clustering has been reported from the Swedish register, which further confirms an association between the two entities.<sup><xref ref-type="bibr" rid="bibr5-1352458511427719">5</xref>,<xref ref-type="bibr" rid="bibr6-1352458511427719">6</xref></sup> This could give clues about the common features that the two disease share. Both diseases have an environmental and genetic component,<sup><xref ref-type="bibr" rid="bibr1-1352458511427719">1</xref>,<xref ref-type="bibr" rid="bibr3-1352458511427719">3</xref></sup> and our results mostly point toward genetic similarities.</p>
<p>The precise cause of MS is still unknown, though the role of autoimmunity in MS is well documented. Nevertheless, there are several lines of evidence supporting the existence of an underlying neurodegenerative process accompanying or even occurring prior to autoimmunity.<sup><xref ref-type="bibr" rid="bibr3-1352458511427719">3</xref></sup> ALS is a neurodegenerative disease and its pathophysiology includes a complex series of factors such as genetics, excitotoxicity, oxidative stress, mitochondrial dysfunction, impaired axonal transport and contribution of immune system.<sup><xref ref-type="bibr" rid="bibr9-1352458511427719">9</xref></sup> Progressive central axonal degeneration is seen in both MS and ALS. There are several genes involved in the axonal transport and defects in some of these genes might be common to both diseases leading to axonal loss.<sup><xref ref-type="bibr" rid="bibr10-1352458511427719">10</xref></sup> One explanation would be that our families share some common genes which predispose to both MS and ALS.</p>
<p>This study had some limitations, including the small number of patients involved and possible incomplete case ascertainment in the original epidemiological studies. The strength of this study was the possibility of studying the association bidirectionally from the two established MS and ALS datasets.<sup><xref ref-type="bibr" rid="bibr7-1352458511427719">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458511427719">8</xref></sup></p>
<p>In conclusion, our results indicate that first degree relatives of MS patients are at a greater risk of acquiring ALS and moreover the first degree relatives of ALS patients are also more likely to get MS. These results should be interpreted cautiously as the observation might be as a result of coincidence; however, the bidirectional significance of the analysis strengthens the fact that the observed results are not solely as a result of chance and deserve more investigations to better clarify the association between MS and ALS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<p>None declared.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511427719">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramagopalan</surname><given-names>SV</given-names></name>
<name><surname>Dobson</surname><given-names>R</given-names></name>
<name><surname>Meier</surname><given-names>UC</given-names></name>
<name><surname>Giovannoni</surname><given-names>G</given-names></name>
</person-group>. <article-title>Multiple sclerosis: risk factors, prodromes, and potential causal pathways</article-title>. <source>Lancet Neurol</source> <year>2010</year>; <volume>9</volume>: <fpage>727</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511427719">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoppenbrouwers</surname><given-names>IA</given-names></name>
<name><surname>Hintzen</surname><given-names>RQ</given-names></name>
</person-group>. <article-title>Genetics of multiple sclerosis</article-title>. <source>Biochim Biophys Acta</source> <year>2010</year>; <volume>1812</volume>: <fpage>194</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511427719">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henderson</surname><given-names>AP</given-names></name>
<name><surname>Barnett</surname><given-names>MH</given-names></name>
<name><surname>Parratt</surname><given-names>JD</given-names></name>
<name><surname>Prineas</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Multiple sclerosis: distribution of inflammatory cells in newly forming lesions</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>739</fpage>–<lpage>753</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511427719">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wijesekera</surname><given-names>LC</given-names></name>
<name><surname>Leigh</surname><given-names>PN</given-names></name>
</person-group>. <article-title>Amyotrophic lateral sclerosis</article-title>. <source>Orphanet J Rare Dis</source> <year>2009</year>; <volume>4</volume>: <fpage>3</fpage>.</citation>
</ref>
<ref id="bibr5-1352458511427719">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hemminki</surname><given-names>K</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Sundquist</surname><given-names>J</given-names></name>
<name><surname>Sundquist</surname><given-names>K</given-names></name>
</person-group>. <article-title>Familial risks for amyotrophic lateral sclerosis and autoimmune diseases</article-title>. <source>Neurogenetics</source> <year>2009</year>; <volume>10</volume>: <fpage>111</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511427719">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hemminki</surname><given-names>K</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Sundquist</surname><given-names>J</given-names></name>
<name><surname>Hillert</surname><given-names>J</given-names></name>
<name><surname>Sundquist</surname><given-names>K</given-names></name>
</person-group>. <article-title>Risk for multiple sclerosis in relatives and spouses of patients diagnosed with autoimmune and related conditions</article-title>. <source>Neurogenetics</source> <year>2009</year>; <volume>10</volume>: <fpage>5</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511427719">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saadatnia</surname><given-names>M</given-names></name>
<name><surname>Etemadifar</surname><given-names>M</given-names></name>
<name><surname>Maghzi</surname><given-names>AH</given-names></name>
</person-group>. <article-title>Multiple sclerosis in Isfahan, Iran</article-title>. <source>Int Rev Neurobiol</source> <year>2007</year>; <volume>79</volume>: <fpage>357</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511427719">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sajjadi</surname><given-names>M</given-names></name>
<name><surname>Etemadifar</surname><given-names>M</given-names></name>
<name><surname>Nemati</surname><given-names>A</given-names></name>
<name><surname>Ghazavi</surname><given-names>H</given-names></name>
<name><surname>Basiri</surname><given-names>K</given-names></name>
<name><surname>Khoundabi</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran</article-title>. <source>Eur J Neurol</source> <year>2010</year>; <volume>17</volume>: <fpage>984</fpage>–<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511427719">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbeito</surname><given-names>AG</given-names></name>
<name><surname>Mesci</surname><given-names>P</given-names></name>
<name><surname>Boillée</surname><given-names>S</given-names></name>
</person-group>. <article-title>Motor neuron–immune interactions: the vicious circle of ALS</article-title>. <source>J Neural Transm</source> <year>2010</year>; <volume>117</volume>: <fpage>981</fpage>–<lpage>1000</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511427719">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ebers</surname><given-names>GC</given-names></name>
</person-group>. <article-title>MS and autoimmune disorders</article-title>. <source>Neurogenetics</source> <year>2009</year>; <volume>10</volume>: <fpage>1</fpage>–<lpage>3</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>